Though treatment of metastatic pancreatic adenocarcinoma (PAC) across Europe generally followed the European Society for Medical Oncology (ESMO) guideline, there weresubstantial geographic variations in treatment patterns used as first-line therapies , according to a retrospective chart review presented at the ESMO World Congress on Gastrointestinal Cancer 2018.
Metastatic PAC outcomes remain poor and treatment options are limited. The purpose of this observational study was to determine the treatment patterns and outcomes of patients with metastatic PAC across Europe. Read more . . .